March 23, 2023
Health Canada Authorizes IMBRUVICA® (ibrutinib) in a Fixed-Duration Combination with Venetoclax for Adult Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)
October 25, 2022
U.S. FDA Approves TECVAYLI (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
January 14, 2021
NOMINATIONS ARE OPEN FOR THE 2021 DR. PAUL JANSSEN AWARD!
No current content.
Connect with us LinkedIn